Portal de Periódicos da CAPES

Updates to the Management of Kidney Cancer

2018; National Comprehensive Cancer; Volume: 16; Issue: 5S Linguagem: Inglês

10.6004/jnccn.2018.0039

1540-1413

Eric Jonasch,

Economic and Financial Impacts of Cancer

Several updates were made to the 2018 NCCN Guidelines for Kidney Cancer. Adjuvant sunitinib is the first adjuvant therapy to be endorsed by the panel for patients with stage II and III clear cell histology renal cell carcinoma (RCC; category 2B). A promising new treatment—ipilimumab plus nivolumab for patients at intermediate and poor risk in the frontline setting—was added to the guidelines as well. Cabozantinib was added as a first-line option for poor- and intermediate-risk patients with advanced RCC.